Abstract: A method of preparing epoxidation catalysts is disclosed. The method comprises: (a) adding an inorganic siliceous solid to a column to produce a solid-filled column; (b) adding to the solid-filled column a solution comprising titanium tetrachloride and a hydrocarbon solvent to produce a titanium tetrachloride-impregnated solid; and (c) calcining the titanium tetrachloride-impregnated solid at a temperature from 500° C. to 1000° C. to produce the catalyst. The inorganic siliceous solid has a pore volume of at least 0.8 cm3/g.

Abstract: A process for the continuous production, through the glycerine route, of epichlorohydrin from dichlorohydrins, in the presence of an alkali solution, wherein the reactive column for the reaction of dichlorohydrin to epichlorohydrin is characterized by single or multiple feed injections and by multiple alkali solution injections, in order to optimize the epichlorohydrin production and to minimize the aqueous effluents in quantity and in organic contaminants.

Abstract: The present invention relates to a biocidal composition including at least one active biocidal compound and at least one nonionic or anionic exopolysaccharide (EPS), the active biocidal compound being selected from at least one triamine having the following formula I, R1NR2R3, formula I where R1 is an aminoalkyl radical comprising a straight or branched chain having 2 to 16 carbon atoms, R2 is a hydrogen atom or a straight or branched alkyl chain having 1 to 18 carbon atoms, and R3 is, independently from R1, an aminoalkyl radical comprising a straight or branched chain having 2 to 16 carbon atoms or a —CH2—CH2—CH2—NH—R4 radical, where R4 is a saturated or unsaturated fatty acid chain including 4 to 20 carbon atoms or a mixture of C4-C20 alkyl chains, characterized in that the biocidal composition includes, by weight and relative to the total weight of said biocidal composition, 0.5 to 90% of the biocidal compound and 0.1 to 10% of the exopolysaccharide.

Abstract: A new process for the manufacture of iodinated xanthenes in high purity includes a cyclization step followed by an iodination step. No extraction, chromatographic or solvent concentration steps are required, and the intermediate as well as final compounds are isolated via filtration or similar means. The process requires a single organic solvent, and the steps are completed at temperatures below 100° C. The exclusion of chloride ions, of chloride free-radicals, hypochlorite ions, or hypochlorous acid as reagents or from reagents that may generate these species in situ in the presence of oxidants, prevents undesirable impurity formation. Several new compounds have been conceived and isolated using these methods. These new compounds are also formed into new medicaments.

Abstract: The present invention relates to methods for improving muscle strength and treating muscular dystrophy.

Abstract: Disclosed herein are compositions that are useful in effecting the transdermal delivery of therapeutic agents. More particularly, the disclosed transdermal compositions may include a fatty alcohol (for example, octanol), a terpene (for example, limonene), and an active agent comprising an amine moiety.

Abstract: A process for reducing the bacterial count on a poultry carcass during poultry processing after the picking stage and prior to the chilling stage by applying an intervention solution having at least one equilibrium peroxycarboxylic acid or a pH modified peroxycarboxylic acid comprising peroxyacetic acid to the poultry carcass at an elevated temperature above 100° F. and at an elevated concentration of at least 200 ppm for a desired period of time of less than about 30 seconds to reduce the bacterial count by at least 60 percent. The process providing acceptable antimicrobial control in poultry processing prior to the chilling stage.

Abstract: The invention describes novel mono or dihydroxy docosahexaenoic acid (DHA) analogs, their preparation, isolation, identification, purification and uses thereof.

Abstract: Provided are various compounds comprising the formula Also provided are fluorescent dyes comprising the above compound. Additionally, a fluorescence energy transfer system is provided that comprises the above-described fluorescent dye and a second dye, wherein the second dye is capable of energy transfer with the fluorescent dye. Further provided is a kit for labeling a target molecule, where the kit comprises the above-described fluorescent dye with additional reagents useful for labeling the target molecule. Additionally provided is a target molecule labeled with the above-described fluorescent dye. Methods of labeling a target molecule with the above-described fluorescent dye are also provided.

Abstract: Methods, catalysts, and reactor systems for producing in high yield aromatic chemicals and liquid fuels from a mixture of oxygenates comprising di- and polyoxygenates are disclosed. Also disclosed are methods, catalysts, and reactor systems for producing aromatic chemicals and liquid fuels from oxygenated hydrocarbons such as carbohydrates, sugars, sugar alcohols, sugar degradation products, and the like; and methods, catalysts, and reactor systems for producing the mixture of oxygenates from oxygenated hydrocarbons such as carbohydrates, sugars, sugar alcohols, sugar degradation products, and the like. The disclosed catalysts for preparing the mixture of oxygenates comprise a NinSnm alloy and a crystalline alumina support.

Abstract: The present invention relates to millepachine ((E)-1-(5-methoxy-2,2-dimethyl-2H-chromen-8-yl)-3-(4-methoxyphenyl)prop-2-en-1-one) and its analogs. The present invention provides methods for preparing these compounds, pharmaceutical compositions including these compounds, and methods of treating diseases utilizing pharmaceutical compositions including these compounds.

Abstract: The present invention relates to the combination of a selective late sodium current blocker and a selective, specific sinus If current inhibitor, and to the pharmaceutical compositions containing said combination.

Abstract: A production method by which an alkyldiol monoglycidyl ether can be efficiently produced without requiring a complex purification step is provided. A method for producing an alkyldiol monoglycidyl ether, including a step of reacting a vinyl ether-containing alcohol with an epihalohydrin to form a vinyl ether-containing glycidyl ether, conducting a devinylation reaction in the presence of an acid catalyst and water, and further conducting an acetal decomposition reaction by adding an acid aqueous solution.

Abstract: There is provided processes for preparing Lubiprostone and intermediates thereof. Also provided are compounds, including intermediates for preparing Lubiprostone as well compositions comprising Lubiprostone and other compounds, including intermediates for preparing Lubiprostone and other compounds.

Abstract: The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, methods of producing these naphthofuran compounds, polymorphs, purified compositions and/or particle forms, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof.

Abstract: Catalysts and methods for the double carbonylation of epoxides are disclosed. Each epoxide molecule reacts with two molecules of carbon monoxide to produce a succinic anhydride. The reaction is facilitated by catalysts combining a Lewis acidic species with a transition metal carbonyl complex. The double carbonylation is achieved in single process by using reaction conditions under which both carbonylation reactions occur without the necessity of isolating or purifying the product of the first carbonylation.

Abstract: The present invention provides a method of screening anti-plasmodial activity of Acriflavin, comprising assessing growth inhibition of plasmodium in vitro in chloroquine susceptible and cloroquine resistant plasmodium by Acriflavin; or measuring in-vivo plasmodium killing ability of Acriflavin; assessing localization of Acriflavin at different stages; and analyzing effect of Acriflavin on gyrase activity wherein said method utilizes Acriflavin in nano-molar range. The present invention relates to potency of Acriflavin (Acriflavin) as an anti-malarial agent both in vitro parasite culture as well as in vivo. More specifically, the invention relates to a method o determining anti-plasmodial activity, Acriflavin as potent anti-malarial agent and also relates to composition(s) comprising Acriflavin.

Abstract: The present invention provides a method for treating an ocular disease in a subject in need thereof, comprising administering an effective amount of a compound of Formula (A) to the subject. Also provided is a pharmaceutical composition for treating an ocular disease, which comprises compound of Formula (A), and a pharmaceutically acceptable carrier.

Abstract: Methods and compositions are provided for the manufacture of an epoxide. In one embodiment, the invention provides a process for the manufacture of an epoxide including providing an olefin, an oxidant, alkaline earth metal ions, a catalyst component, a buffer component, and water to form a reaction mixture and reacting the olefin with the oxidant in the reaction mixture.

Abstract: The present disclosure relates to: (a) stabilized pharmaceutical dosage forms comprising atrasenstan, or a pharmaceutically acceptable salt thereof, and, optionally, another therapeutic agent; (b) methods of using such pharmaceutical dosage forms to treat nephropathy, chronic kidney disease, and/or other conditions; (c) kits comprising such pharmaceutical dosage forms and, optionally, a second pharmaceutical dosage form comprising another therapeutic agent; (d) methods for the preparation of such pharmaceutical dosage forms; and (e) pharmaceutical dosage forms prepared by such methods.